Insights & Resources

For venture capital fund managers, understanding the Qualified Small Business Stock (QSBS) exemption presents a lucrative opportunity. Learn more in this overview.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

FinCEN suspends Corporate Transparency Act reporting deadlines following order granting a preliminary injunction in federal district court in Texas.

Selecting an entity type in real estate is often decided by issues like tax flexibility. Here are some of the key considerations to keep in mind.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

The initial enthusiasm for ESG in financial services was met with increased scrutiny, but the underlying ESG principles continue to hold sway.

A recent U.S. complaint highlights the growing need for health care systems to ensure physician compensation aligns with fair market value to avoid compliance risks.

Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.

The instances of urgent care clinic visits have returned to pre-pandemic levels, but COVID-related services still make up a large percentage of the total volume.

California issued new financial statement requirements that are effective as of January of last year for skilled nursing facilities (SNF).

Managing revenue cycles is an important aspect of modern hospital operations. Defined business processes and strong internal controls are the keys to optimization.